Navigation Links
NexBio to Present at 2007 BIOCOM Investor Conference

SAN DIEGO, Oct. 31 /PRNewswire/ -- NexBio, Inc. a privately held development-stage biopharmaceutical company located in San Diego, announced today that Dr. David Wurtman, its Vice President of Corporate Development, will present a corporate overview and update at the BIOCOM Investor Conference on November 1, 2007.

NexBio's mission is to save lives, and to improve the quality of life, by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening human viral respiratory diseases. NexBio has received significant financial support through grants and contracts from the National Institutes of Health for development of Fludase(TM), its lead program, a first-in-class broad-spectrum prophylactic and therapeutic agent to potentially address all annual and pandemic variations of influenza, including the Avian IFV H5N1 ("Bird Flu"), as well as parainfluenza. Product candidates in NexBio's pipeline may address additional viral infections, such as RSV.

The company also possesses TOSAP(TM), a novel, elegant, flexible & scalable formulation technology, invented by NexBio scientists, which it uses to make dry-powder microspheres to allow drugs to be delivered by inhalation. TOSAP(TM) is being applied to expand the company's pipeline, and is also being licensed to partners who wish to formulate their own compounds.

NexBio is actively seeking corporate partnerships from companies that have extensive experience in late stage drug development and commercialization, as well as entertaining inquiries from financing sources that may wish to invest in the company.

For more information about NexBio, Inc., please visit


David Wurtman, M.D., M.B.A

VP, Corporate Development

10665 Sorrento Valley Road

San Diego, CA 92121

Phone: (858) 452-2631

Note: FDA has yet to approve the name Fludase.

SOURCE NexBio, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
Breaking Medicine Technology: